Genome Analysis of Human Endogenous Retroviruses (HERVs) and Gut Microbiota in Patients With SARS-CoV-2 Infection, Kawasaki Disease and Other Febrile and Inflammatory Diseases With Systemic Involvement in Pediatric Age.

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Human Endogenous Retroviruses (HERVs) are ancient sequences that became integrated into our DNA during evolutionary processes. The significance of their presence in DNA is still being studied, but HERVs appear to be involved in the regulation of the immune response. The gut microbiota is the set of microorganisms that physiologically colonize the gastrointestinal tract. Progressively increasing attention is being paid to the gut microbiota and its potential role in diseases of various kinds. In particular, it has recently been shown how abnormalities in the microbiota can affect immune regulation by determining the occurrence of certain diseases. One objective of the study is to evaluate whether there is an association between the expression of HERVs and clinical manifestations in pediatric age in patients with various diseases such as Kawasaki Disease, IgA Vasculitis/Schonlein-Henoch's Purpura, SARS-CoV-2 infection, or, finally, febrile virosis. Another objective of the study is to evaluate whether there is an association between the presence of particular types of bacteria in the gut microbiota and clinical manifestations in pediatric age in patients with Kawasaki Disease, IgA Vasculitis/Schonlein-Henoch purpura, SARS-CoV-2 infection or febrile virosis. The results from this may open new perspectives for both the care and therapeutic management of children with these diseases.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:

• Pediatric patients, newly diagnosed with Kawasaki disease

• Pediatric patients, newly diagnosed with Vasculitis

• Pediatric patients, newly diagnosed with SARS-CoV-2 infection

• Pediatric patients, newly diagnosed with febrile virosis

• Pediatric patients with inflammatory diseases with systemic involvement

Locations
Other Locations
Italy
IRCCS Azienda Ospedaliero - Universitaria di Bologna, U.O. Pediatria d'Urgenza, Pronto Soccorso e Osservazione Breve ed Intensiva
RECRUITING
Bologna
Ospedale Ramazzini di Carpi, Azienda USL di Modena UO Pediatria
RECRUITING
Carpi
Azienda Ospedaliera-Universitaria di Modena
RECRUITING
Modena
IRCCS Ospedale Pediatrico Bambino Gesù UOC Pediatria Generale
RECRUITING
Roma
Ospedale Regina Margherita, Torino, UO Reumatologia Pediatrica
RECRUITING
Torino
Contact Information
Primary
Marianna Fabi, MD
marianna.fabi@aosp.bo.it
0512143012
Time Frame
Start Date: 2021-06-10
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 120
Treatments
Experimental: Patients
The study will be offered consecutively to each patient in whom Kawasaki Disease, Schonlein-Henoch purpura, symptomatic SARS-CoV-2 infection, febrile virosis, and with inflammatory diseases with systemic involvement are diagnosed.
Sponsors
Leads: IRCCS Azienda Ospedaliero-Universitaria di Bologna

This content was sourced from clinicaltrials.gov

Similar Clinical Trials